Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy
- 16 October 2021
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 100 (6) , 1208-1213
Abstract
No abstract availableKeywords
Funding Information
- National Multiple Sclerosis Society (R-1705-27628)
- U.S. Department of Veterans Affairs (B7493-W)
- U.S. Department of Veterans Affairs (I01 RX002682-01)
- National Institutes of Health
- MS Canada (1073-A-4)
- National Center for Advancing Translational Sciences (UL1TR002369)
This publication has 23 references indexed in Scilit:
- Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic PolyneuropathyDiabetes Care, 2011
- Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous NephropathyNew England Journal of Medicine, 2011
- Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2010
- Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the NetherlandsNephrology Dialysis Transplantation, 2008
- α-Lipoic Acid and Insulin Autoimmune SyndromeDiabetes Care, 2007
- MethyldopaArchives of internal medicine (1960), 1980
- Methyldopa. Mechanisms and treatment 25 years laterArchives of internal medicine (1960), 1980
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978